In summary, our results establish hepatic PTP4A1-mediated activation of the CREBH/FGF21 axis as a novel therapeutic strategy in NAFLD and hyperglycemia. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatotic liver disease.